Stockscreener 앱 받기
136.90
2.89%
-4.08
시간 외 거래:
136.90
전일 마감가:
$140.98
열려 있는:
$137.99
하루 거래량:
1.67M
Relative Volume:
1.54
시가총액:
$7.00B
수익:
$4.06B
순이익/손실:
$413.08M
주가수익비율:
17.09
EPS:
8.01
순현금흐름:
$560.48M
1주 성능:
-11.99%
1개월 성능:
-16.68%
6개월 성능:
-28.23%
1년 성능:
-45.38%
1일 변동 폭
$132.99
$140.15
1주일 범위
$132.99
$153.81
52주 변동 폭
$132.99
$258.56
Charles River Laboratories International Inc Stock (CRL) Company Profile
명칭
Charles River Laboratories International Inc
전화
781-222-6000
주소
251 BALLARDVALE ST, WILMINGTON, MA
CRL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
136.90 | 7.00B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
437.91 | 165.21B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
181.77 | 130.05B | 23.88B | 3.90B | 5.30B | 5.28 |
|
IDXX
Idexx Laboratories Inc
|
393.73 | 31.91B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
103.00 | 29.38B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
154.73 | 27.28B | 15.41B | 1.37B | 2.11B | 7.50 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-21 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-03-04 | 업그레이드 | Citigroup | Sell → Neutral |
| 2025-03-03 | 업그레이드 | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-11-18 | 다운그레이드 | CLSA | Hold → Underperform |
| 2024-11-07 | 업그레이드 | CLSA | Underperform → Hold |
| 2024-10-23 | 개시 | CLSA | Underperform |
| 2024-10-14 | 개시 | Redburn Atlantic | Sell |
| 2024-10-07 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-10-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-01 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2024-08-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-08-08 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | 다운그레이드 | Argus | Buy → Hold |
| 2024-06-07 | 개시 | Mizuho | Neutral |
| 2024-06-06 | 개시 | Goldman | Buy |
| 2024-02-15 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-09-13 | 개시 | TD Cowen | Market Perform |
| 2023-07-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-02-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-01-12 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-09-30 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-08-04 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | 개시 | Guggenheim | Neutral |
| 2022-04-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-04-07 | 개시 | Stephens | Overweight |
| 2022-02-17 | 재확인 | BofA Securities | Buy |
| 2022-02-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-02-17 | 재확인 | Deutsche Bank | Buy |
| 2022-02-17 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-17 | 재확인 | UBS | Buy |
| 2021-08-05 | 재개 | Credit Suisse | Neutral |
| 2020-12-16 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-09-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-07-01 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-05-13 | 업그레이드 | UBS | Neutral → Buy |
| 2020-04-21 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-03-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | 개시 | Deutsche Bank | Buy |
| 2020-02-18 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-01-08 | 개시 | Wells Fargo | Overweight |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-10-18 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | 개시 | SVB Leerink | Outperform |
| 2019-04-30 | 재개 | Evercore ISI | Outperform |
| 2018-12-14 | 개시 | Deutsche Bank | Buy |
| 2018-10-09 | 개시 | UBS | Neutral |
| 2018-08-23 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | 업그레이드 | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | 업그레이드 | SunTrust | Hold → Buy |
모두보기
Charles River Laboratories International Inc 주식(CRL)의 최신 뉴스
How Is Charles River Laboratories' Stock Performance Compared to Other Health Care Stocks? - MSN
Human Microbiome Sequencing Market Key Players Analysis - openPR.com
Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Charles River Integrates Akron Bio’s CSS Line of Liquid Cytokines - Contract Pharma
Charles River Labs stock hits 52-week low at $150.19 By Investing.com - Investing.com Australia
Charles River & Valo Health's Logica Identifies New Lupus Drug Candidate - MSN
Baird Adjusts Charles River Laboratories International Price Target to $155 From $173, Maintains Neutral Rating - MarketScreener
Charles River Labs stock hits 52-week low at $150.19 - Investing.com
Mawer Investment Management Ltd. Buys 5,769 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River Laboratories Stock Outlook: Is Wall Street Bullish or Bearish? - MSN
Genetic Toxicology Testing Market To Witness Huge Gains Over - openPR
Biopharma Layoffs Roundup - Contract Pharma
Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform - BioSpace
Charles River, Valo Health Identify First Lupus Treatment Candidate Using Logica AI Platform - Marketscreener.com
Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica - Business Wire
Why Charles River Laboratories International, Inc. (CRL) is Among the Best Diagnostics Stocks to Invest in Right Now - Insider Monkey
12 Best Diagnostics Stocks to Invest In Right Now - Insider Monkey
Goldman Sachs Downgrades Charles River Laboratories International (CRL) - MSN
Demystifying Charles River: Insights From 10 Analyst Reviews - Benzinga
Icon stock, Charles River stock downgraded at Goldman (CRL) - Seeking Alpha
Charles River (CRL) Up 1.9% Since Last Earnings Report: Can It Continue? - Yahoo Finance
This FedEx Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday - Benzinga India
Goldman Sachs cuts Charles River Labs stock rating, target to $170 - Investing.com India
Goldman Sachs cuts Charles River Labs stock rating, target to $170 By Investing.com - Investing.com South Africa
Goldman Sachs Downgrades Charles River Laboratories International to Neutral From Buy, Adjusts Price Target to $170 From $190 - Marketscreener.com
Jefferies maintains Charles River Labs stock hold, price target at $169 - Investing.com Canada
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Interesting CRL Put And Call Options For November 21st - Nasdaq
Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Recent Stock Performance Influenced By Its Fundamentals In Any Way? - Yahoo Finance
Earnings call transcript: Charles River Labs beats Q4 2024 forecasts By Investing.com - Investing.com UK
Should You Investigate Charles River Laboratories International, Inc. (NYSE:CRL) At US$171? - Simply Wall St
Charles River Laboratories to Present at Barclays Global Healthcare Conference - BioSpace
Molecular Breeding Market Insights, Competitive Intelligence and Growth Forecast 2025-2030 - GlobeNewswire Inc.
Charles River Labs Management Reveals Strategic Roadmap at Major Healthcare Conference - Stock Titan
Mutual of America Capital Management LLC Lowers Position in Charles River Laboratories International, Inc. (NYSE:CRL) - Defense World
Smartleaf Asset Management LLC Increases Position in Charles River Laboratories International, Inc. (NYSE:CRL) - Defense World
Fairjourney Biologics acquires Charles River Laboratories South San Francisco facility - MSN
Charles River Laboratories International, Inc. (NYSE:CRL) Q4 2024 Earnings Call Transcript - MSN
Charles River, LabCorp upgraded, Quest downgraded at Citi on valuation - MSN
Charles River announces agreement with Singapore General Hospital - SelectScience
Charles River Laboratories International (NYSE:CRL) Stock Rating Upgraded by Citigroup - Defense World
Reasons to Retain Charles River Stock in Your Portfolio for Now - Yahoo Finance
Global Cell and Gene Therapy Manufacturing Market to Reach ~USD 10 Billion by 2032 | DelveInsight - GlobeNewswire Inc.
Charles River Laboratories Shares Rise After Citigroup Upgrade -March 04, 2025 at 02:53 pm EST - Marketscreener.com
Citi raises Charles River stock rating, lifts target to $175 - Investing.com
Charles River Laboratories International Inc (CRL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.49%
자본화:
|
볼륨(24시간):